Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3+
SponsorPeter MacCallum Cancer Centre, Australia

About this trial

This project seeks to perform whole genome sequence (WGS) and whole transcriptome sequence (WTS) analysis on 350 patients with suspected inherited bone marrow failure syndromes and related disorder (IBMFS-RD) in order to increase the genomic diagnostic rate in IBMFS.

Eligibility criteria

Qualifiers

age ≥ 3 months

able to give informed consent (or parent/guardian able to give informed consent)

a clinicopathological diagnosis (or differential diagnosis) of inherited bone marrow failure syndrome or related disorder (IBMFS-RD) as per the study team

Disqualifiers

A clinicopathological diagnosis of an acquired bone marrow failure syndrome (including acquired aplastic anaemia and hypoplastic myelodysplastic syndrome) as per the study team

Existing definitive genomic diagnosis for patient's haematological phenotype

Trial design

Treatments tested in this trial

  • whole genome and transcriptome sequencing

Treatment groups

No treatment groups listed

Sponsors and collaborators

Peter MacCallum Cancer Centre, Australia

Lead sponsor

National Health and Medical Research Council, Australia

Collaborator

University of Melbourne

Collaborator